Drug Discovery for Neurodegeneration

神经退行性疾病的药物发现

• 批准号: 7332301
• 负责人: Howard M. Fillit
• 金额: $ 7.5万
• 依托单位: ALZHEIMER'S DRUG DISCOVERY FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-15 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7332301
• 关键词: Academia; Academic Training; Address; Alzheimer' s Disease; Amyotrophic Lateral Sclerosis; Area; Basic Science; Biotechnology; Budgets; Comb animal structure; Development; Discipline; Disease; District of Columbia; Drug Industry; Education; Foundations; Goals; Huntington Disease; Incidence; Industry; Information Resources; Institution; Iron binding capacity measurement; Journals; Knowledge; Lead; Learning; Minority; Nerve Degeneration; Neurodegenerative Disorders; POMC gene; Parkinson Disease; Participant; Peer Review; Pharmaceutical Preparations; Process; Public Health; Publishing; Purpose; Range; Research; Research Personnel; Resources; Scientist; Services; Students; Therapeutic Intervention; Time; Training; Translating; United States National Institutes of Health; Validation; Woman; Work; concept; cost; day; drug development; drug discovery; next generation; novel therapeutics; pre-clinical; pre-clinical research; prevent; skills; symposium

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation's (ADDF) conference entitled Drug Discovery for Neurodegeneration will be held on February 4-5, 2008 in the Washington, DC area. The purpose of the conference is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutic interventions. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside the pharmaceutical industry for scientists to learn about these processes. The goals of the conference are consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combing skills and disciplines; to provide networking opportunities for these scientists to exchange ideas and resources; and to publish the proceedings in a peer-reviewed scientific journal. This two-day conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will also address the barriers and challenges associated with the following sub-topics: Target Identification & Validation; Lead Identification & Optimization; Lead Discovery; Pre-Clinical Proof-of-Concept & Development; Resources and Services for Advancing Drug Discovery; and Disease Specific Issues in Drug Discovery for Neurodegenerative Disease. Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis will be included in the discussions. Sessions will consist of 3 to 5 presentations with ample time for Q&A. With respect to the public-private partnership initiative of the Roadmap, ADDF will invite approximately 25 internationally recognized scientists, including women and minorities, from academia, the biotechnology and pharmaceutical industries, as well as the NIH, to serve as chairs or speakers. It is anticipated that this conference will serve an audience of 150 scientists from diverse backgrounds, of which 27% will be women, minorities, young/junior investigators, and graduate students. The public health problem ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis. By offering this conference, ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying products. CTITIQUE 1: Objectives: Training of academic scientists in drug discovery, exchange of ideas, stimulate pre-clinical research, build public-private partnerships, publish proceedings, provide CME credits. 6 topics: targets, leads identification, lead optimization, pre-clinical POC, drug discovery resources, disease-specific issues. The confirmed and proposed speakers include senior and well recognized successful scientists in drug development from both industry and academics. Overall, the proposed conference would likely be quite useful to its targeted audience of academic investigators and would likely accomplish its goal of educating these investigators in drug development and would facilitate public-private partnerships. These activities would strengthen the quality of translational proposals submitted to the NIH. The four targeted disease areas of AD, PD, HD and ALS are quite appropriate for the neurodegenerative field. The focus of training academic scientists in the full range of drug discovery and development from target validation through IND work remains rare although IBC sponsors conferences that include some of these areas. It would be helpful to point out in more specific terms how the proposed conference compares to and is advantageous to these other conferences. The range and expertise of speakers could be broadened by decreasing some of the potential redundancy in which two or more speakers are from the same institution. The proportion of speakers who have actually made a direct and major contribution to the successful development of an approved drug should be increased. Budget: The overall budget is appropriate and the amount requested from NIA (less than half the total cost of the conference) is appropriate. Inclusion of women and minorities is appropriate.

描述（由申请人提供）：阿尔茨海默氏症的药物发现基金会（ADDF）会议题为《神经变性的药物发现》将于2008年2月4日至5日在华盛顿特区举行。会议的目的是通过训练下一代科学领导者在将基础研究转化为新的治疗干预措施的过程中，以推进神经退行性疾病的药物发现。需要对此主题进行正规教育，因为在这一研究领域存在有记录的知识差距，并且在制药行业之外，科学家几乎没有机会了解这些过程。会议的目标与NIH的路线图一致：弥合药物发现和神经退行性疾病的知识差距；将跨学科的科学家汇集在一起​​，以刺激新的梳理技能和学科方式；为这些科学家提供交流思想和资源的网络机会；并在同行评审的科学杂志中发布程序。为期两天的会议将为参与者提供基础知识和创建新药物来治疗和预防神经退行性疾病的知识。它还将解决与以下子主题相关的障碍和挑战：目标识别和验证；铅识别和优化；铅发现；临床前概念证明与发展；用于推进药物发现的资源和服务；和疾病的特定于神经退行性疾病的药物发现。讨论中将包括阿尔茨海默氏病，帕金森氏病，亨廷顿氏病和肌萎缩性侧索硬化症。会议将由3到5个演示文稿组成，有足够的时间进行问答。关于路线图的公私合作伙伴计划，ADDF将邀请大约25名国际认可的科学家，包括妇女和少数民族，来自学术界，生物技术和制药行业以及NIH，作为主持人或演讲者。预计这次会议将为来自不同背景的150名科学家提供的观众，其中27％将是妇女，少数民族，年轻/初级调查员和研究生。公共卫生问题ADDF寻求解决的方法是减少神经退行性疾病的发生率，例如阿尔茨海默氏病，帕金森氏病，亨廷顿氏病和肌萎缩性侧面硬化症。通过提供本次会议，ADDF将增加科学家对药物发现过程的了解，并促进它们共同开发商业可行和有效的疾病修饰产品。 Ctitique 1： 目标：在药物发现，思想交流，刺激临床前研究，建立公私合作伙伴关系，发布程序，提供CME学分的培训。 6个主题：目标，铅识别，铅优化，临床前POC，药物发现资源，特定于疾病的问题。已确认的和拟议的演讲者包括来自行业和学者的高级和公认的药物开发方面的成功科学家。 总体而言，拟议的会议可能对其目标受众的学术研究人员来说可能非常有用，并且可能会实现其对这些研究人员进行药物开发的教育的目标，并将促进公私伙伴关系。这些活动将加强提交给NIH的转化建议的质量。 AD，PD，HD和ALS的四个靶向疾病区域非常适合神经退行性领域。尽管IBC赞助商会议包括其中一些领域，但在目标验证到IND工作的全部药物发现和开发中培训学术科学家的重点仍然很少。用更具体的术语指出拟议的会议对其他会议的比较和有利的方式将有所帮助。可以通过减少两个或多个演讲者来自同一机构的潜在冗余来扩大演讲者的范围和专业知识。实际上对成功开发批准药物的直接和重大贡献的发言人的比例应增加。 预算：总体预算是适当的，NIA要求的金额（少于会议总成本）是合适的。 包括妇女和少数民族是合适的。